Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04231851 · ClinicalTrials.gov registry record · Phase 2
CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia
A Phase 2 study of Acute Myeloid Leukemia With Myelodysplasia-Related Changes and Acute Myelogenous Leukemia (AML) Due to Therapy, sponsored by University of California, Irvine.
- Active
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 4
- Study locations
NCT04231851 is a Phase 2 study of Acute Myeloid Leukemia With Myelodysplasia-Related Changes and Acute Myelogenous Leukemia (AML) Due to Therapy that is active but no longer recruiting, run by University of California, Irvine. The registered enrollment target is 30 participants, below the 180-participant average among 4 other Acute Myeloid Leukemia With Myelodysplasia-Related Changes trials with a reported enrollment target (83% lower). The trial reports 4 study locations across 1 state.
The verdict
NCT04231851, a Phase 2 study of Acute Myeloid Leukemia With Myelodysplasia-Related Changes and Acute Myelogenous Leukemia (AML) Due to Therapy, is active but no longer recruiting, sponsored by University of California, Irvine.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a phase 2 single-arm, open-label clinical trial determining efficacy of CPX-351 in combination with Glasdegib in subjects with Acute Myelogenous Leukemia with myelodysplastic syndrome related changes or therapy-related acute myeloid leukemia.
Conditions Studied
Interventions
- DRUG CPX-351
- DRUG Glasdegib
Study Locations (4)
California
- University of California, Los Angeles - Los Angeles
- Chao Family Comprehensive Cancer Center, University of California, Irvine - Orange
- University of California, Davis - Sacramento
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2020-02-19 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04231851
The ClinicalTrials.gov registry entry for NCT04231851 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 180-participant average among 4 other Acute Myeloid Leukemia With Myelodysplasia-Related Changes trials with a reported enrollment target (83% lower). The listed sponsor is University of California, Irvine, which has 368 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Acute Myeloid Leukemia With Myelodysplasia-Related Changes appearing as the primary indexed condition, and to 2 interventions - of which CPX-351 is the first listed.
NCT04231851 reports 4 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04231851 about?
NCT04231851 is a clinical study titled "CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia". This is a phase 2 single-arm, open-label clinical trial determining efficacy of CPX-351 in combination with Glasdegib in subjects with Acute Myelogenous Leukemia with myelodysplastic syndrome related changes or therapy-related acute myeloid leukemia.
What is the current status of trial NCT04231851?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2020-02-19. Estimated completion is 2027-06-30.
What conditions does trial NCT04231851 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Myelogenous Leukemia (AML) Due to Therapy.
What interventions are being tested in trial NCT04231851?
The interventions under investigation include: CPX-351 (DRUG), Glasdegib (DRUG).
Who is sponsoring clinical trial NCT04231851?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04231851 being conducted?
This trial has 4 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia With Myelodysplasia-Related Changes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Personalized NK Cell Therapy in CBT
RECRUITING · Phase 2
-
CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old
ACTIVE NOT RECRUITING · Phase 2
-
Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia
COMPLETED · Phase 2
-
Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Acute Myeloid Leukemia With Myelodysplasia-Related Changes
All registered trials for this condition
Acute Myelogenous Leukemia (AML) Due to Therapy
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.